AlphAIAlphAI — Financial news for AI agents
MarketBeatAPR 302 min read$ASPS

Altisource Portfolio Solutions (ASPS) to Post Earnings on Thursday

Altisource Portfolio Solutions (NASDAQ:ASPS) is scheduled to release its Q1 2026 earnings before market open on Thursday, May 7th. Analysts anticipate earnings of $0.18 per share and $39.80 million in revenue. The company previously exceeded estimates in Q4, reporting $0.19 EPS against an expected $0.09 and $45.09 million in revenue.

Original reporting
MarketBeat · MarketBeat
Published Apr 30, 2026, 6:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 30, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Altisource Portfolio Solutions (ASPS) to Post Earnings on Thursday — source image
Source · MarketBeat
Decision brief

The 30-second read

$ASPSNeutralMed
01

Why it matters

Earnings release may influence stock price volatility; positive results could reinforce sector strength.

02

Market read

The upcoming earnings are relevant for traders focusing on real estate and financial sectors, with moderate impact expected.

03

What to watch

Potential macroeconomic factors or company-specific issues not reflected in current estimates could impact results.

Relevance 6/10Timing: High, as earnings are scheduled for May 7, 2026.

Background

Altisource Portfolio Solutions operates in real estate and mortgage services, with recent performance exceeding expectations in Q4 2025.

Company-level read

Ticker impact

$ASPSNeutralMedium confidence
Context

The upcoming earnings report is highly relevant for short-term trading decisions.

Expected impact

Potential for slight positive movement if earnings meet or exceed expectations; risk of decline if results fall short.

Evidence & confidence

Earnings are expected to be in line with estimates, and previous quarter exceeded expectations, suggesting stability but limited upside.

Market effects

Sector

Positive sentiment in the financial services and real estate sectors due to improved earnings outlooks.

Regional

Limited regional impact; primarily affecting US-based financial and real estate stocks.

Global

Minimal, as Altisource operates mainly within the US.

Counterpoint

What could challenge this read

Earnings may underperform due to industry headwinds, leading to a short-term decline.

Key entities

  • Company
    Altisource Portfolio Solutions

    A provider of real estate and mortgage services.

Read at source← All news

Related articles

JUL 24
$ASPSMed

Altisource Portfolio Solutions Q2 Earnings Call Highlights

Altisource Portfolio Solutions (NASDAQ:ASPS) reported Q2 GAAP pre-tax earnings near breakeven versus $200,000 in Q2 2025. Operating cash flow used $6.6 million, with unrestricted cash of $23.2 million. Service revenue rose to $34.4 million (+8% YoY) and segment adjusted EBITDA was $11.7 million. Management cited customer wins, debt repurchases, and expects roughly flat Q3 adjusted EBITDA and higher Q4.

yahoo.com7 min
JUL 23
$ASPSMed

ALTISOURCE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

ALTISOURCE PORTFOLIO SOLUTIONS S.A. (ASPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE FOR FURTHER INFORMATION CONTACT: Michelle D. Esterman Chief Financial Officer T: (770) 612-7007 E: Michelle.Esterman@altisource.com ALTISOURCE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESU

SEC EDGAR 8-K4 min
OCT 24
$CMPXMedAI 8/10

Compass Therapeutics publishes tovecimig trial results in JCO

Compass Therapeutics (NASDAQ:CMPX) published Phase 2/3 trial results for tovecimig in the Journal of Clinical Oncology. The study met primary and secondary endpoints, showing improved response rates and progression-free survival in advanced biliary tract cancer patients compared to paclitaxel alone. However, overall survival showed no significant difference, and adverse events were higher in the combination arm. Tovecimig remains investigational.

investing.com2 min